jfm1330 wrote: I got my seventh Lu177-Dotate treatment yesterday. It is funny because the two doctors in charge yesterday were two doctors I met for the first time, so they did not know my scientific background, so they after asking me how I felt physically, the fist thing they told me is that they were giving me two new cycles of treatement with this drug because I was still overexpressing somatostatin receptors on a recent scan, with no trace of other cancer types on another scan type. So one of the doctor told me: "we think this treatment will still be beneficial for you because of that". In other words, she was telling me that they were not doing it blindly, they had a strong scientific case to justify treatment. I understand that Thera is not at this stage with TH1902, but still, it shows the difference and why they need to develop an sortilin imaging method. The technology is out there, they just need to apply it to their peptide and do the development work that needs to be done to have it approved.
It's not even a full 24 hours since they injected me the drug and I aleready feel the benefits. I had pain in my one of my left ribs with a metestatic tumor, painful enough to not be able to sleep on my left side, and even yesterday, before going to bed, the pain is much lower. I was able to sleep on my left side last night without feeling pain. Also, in the last few months, my main symptom was huge fatigue related to hormone secretion by the tumors. On average I was sleeping 10 hours a day without feeling refreshed after sleep and I was no longer to do long bike rides. Today I was awake at six, after only 8 hours of sleep, and I feel no fatigue. All that after only sleeping 13 hours the two previous nights since I needed to change my sleeping pttern to wake up at 4 in the night to drive to hospital and be sure to be there at 7. Obviously it is anecdotal, but I feel clearly better after less than a day. I will see if it continues in the days and weeks to come. I will have a second treatment in three months.
I am telling you this experience just to show that efficacy in a targeted treatment is linked to target overexpression on tumors. It should Thera's top priority, other than the current trial, to work on a solution to determine sortilin overexpression before treatment. In my case, if doctors would have told me yesterday that they did not know if I still had somatostatin receptor overexpression, and that they were giving me the treatment in the hope I still had overexpression, it would have been much less enticing to go through that process. I was motivated to have it because I knew it worked on me in the past and the odds of it still working to some extent were high. Obviously if it would have been my last hope I would have taken it anyway, but if Thera wants to make a rn in less advanced patients and not be limited to last line therapy, they need to start to work now on sortilin imaging. Sortilin imaging is to TH1902, what drug formulation was to Egrifta. Now what the way they operate with Th1902 is clearly subpar, like the were subpar with F1 formulation of Egrifta. They can continue for a while without sortilin imaging while in clinical trial, but they need to have something ready, or close to it, for potential commercialization.
SPCEO1 wrote: Thank you, as well as all the others, for your condlences.
Regarding your "all comers" comment - you are well behind the times on that as it only applied to the phase 1a. Phase 1b is indeed targeting cancers their pre-clinical work showed had high sortilin expression. So, there is one worry you don't have to concern yourself with now. It is true they are not doing a diagnostic test to prove sortilin overexpression with phase 1b patients but there is a high probability the patients in the phase 1b do indeed overexpress sortilin receptors.